Prevail Partners and Prevail InfoWorks Enter Into Strategic Investment and Clinical Alliance With Kairos Pharma, Ltd.

PHILADELPHIA, PA / ACCESSWIRE / September 25, 2024 / Prevail Partners LLC (“Prevail Partners”) and Prevail InfoWorks Inc. (“Prevail InfoWorks”) announce that they have entered into a strategic relationship with Kairos Pharma, Ltd. (“Kairos”), a clinical stage biopharmaceutical company located in Los Angeles, California, and the developer of innovative therapeutics that aim to reverse cancer resistance against standard of care therapeutics. Under the relationship, Prevail Partners, a life sciences investment fund, participated in the Initial Public Offering of Kairos, which became listed on the New York Stock Exchange on September 16, 2024.

Prevail InfoWorks, a global full-service Clinical Research Organization, has agreed to support Kairos with clinical services and technologies in two upcoming clinical trials: a phase II randomized multi-institutional trial of ENV 105 for patients with castrate-resistant prostate cancer and a phase I trial of ENV 105 in patients with EGFR-driven lung cancer who have developed partial or complete resistance to Osimertinib. Prevail InfoWorks will provide its Single InterfaceTM Integrated Analytics Platform and lead the project management for both trials, as well as provide site management, monitoring, and pharmacovigilance.

Mary Schaheen, President of Prevail Partners, said: “There is a substantial unmet need to address resistance to hormone and EGFR therapies for multiple cancer types that develop through the upregulation of CD105. Through our strategic investment and the clinical services of our affiliate, we are excited to support Kairos Pharma’s well-designed trials for testing INV 105, which aims to target CD105 signaling to reverse cancer drug resistance.”

About Prevail Partners, LLC

Prevail Partners, LLC is a corporate strategic investment fund investing in clinical stage therapeutics companies. More information is available at https://prevailpartners.com.

About Prevail InfoWorks, Inc.

Prevail InfoWorks, Inc. is a global full-service CRO/FSP and one-stop-shop for clinical trial services and systems. More information is available at https://prevailinfoworks.com.

About Kairos Pharma, Ltd.

Kairos Pharma, a clinical-stage biopharmaceutical company advancing therapeutics that reverse cancer drug resistance and immune suppression through the power of structural biology. More information is available https://kairospharma.com.

Contact Information

Henry Ehlers
Associate
henry.ehlers@prevailpartners.com
267-797-2043

SOURCE: Prevail Partners

View the original press release on newswire.com.

Staff

Recent Posts

RIVANNA secures patent for groundbreaking ultrasound-guided needle insertion system

CHARLOTTESVILLE, Va., Sept. 25, 2024 /PRNewswire/ -- RIVANNA®, developers of world-first imaging-based medical solutions, announced…

3 hours ago

Mediwhale Secures $12 Million in Series A2 Funding to Drive Global Leadership in Cardiovascular and Metabolic Disease Management

SEOUL, South Korea, Sept. 25, 2024 /PRNewswire/ -- Mediwhale, the AI-powered health diagnostics company, announced $12 million…

3 hours ago

Medicat Makes Immunization Compliance Easier at Leading Universities

ATLANTA, Sept. 25, 2024 /PRNewswire/ -- Medicat, the #1 provider of Electronic Health Records (EHR)…

3 hours ago

CAQH Names Ashley Blankette as Chief Product Officer to Lead Provider and Member Data Solutions

Ashley Blankette joins CAQH to lead product strategy and development for provider and member data…

3 hours ago

Piwik PRO Achieves HIPAA Certification, Enabling Data-Driven Marketing and Privacy Compliance for Healthcare Organizations

Ensures compliance for secure and privacy-friendly digital analytics in healthcare WROCŁAW, Poland, Sept. 25, 2024…

3 hours ago

Coalition for Patient Rights (CPR) Urges Immediate Medical Cannabis Law Reform in Nevada with Broad Support from Integrative Healthcare

Compassion Center celebrates and champions the Coalition for Patient Rights (CPR) in leading the charge…

3 hours ago